E C Schwaneck1, A Streit2, M Krone3, S Hartmann4, U Müller-Richter4, A C Kübler4, O Gadeholt2, M Schmalzing2, H-P Tony2, R C Brands4. 1. Department of Rheumatology and Immunology (Head: H.-P. Tony), University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. Schwaneck_E@ukw.de. 2. Department of Rheumatology and Immunology (Head: H.-P. Tony), University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. 3. Institute for Hygiene and Microbiology, University of Wuerzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany. 4. Department of Oral and Maxillofacial Plastic Surgery (Head: A.C. Kübler), University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
Abstract
BACKGROUND AND OBJECTIVES: The aim of the present study was to assess the prevalence of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients suffering from inflammatory rheumatic diseases, as well as to assess the prevalence of relevant dental, behavioral, and medical risk factors for MRONJ. MATERIALS AND METHODS: A total of 198 patients with inflammatory rheumatic diseases and osteoporosis therapy were recruited from a tertiary rheumatological/immunological referral center between June 2015 and September 2016. They were assessed using a structured interview. A maxillofacial surgeon later examined patients complaining of possible symptoms of osteonecrosis. In cases of osteonecrosis, dental records were obtained and evaluated. Preventive measures taken and dental as well as other clinical risk factors were evaluated. RESULTS: Of the 198 patients, three suffered from osteonecrosis of the jaw, none of whom had any history of malignant disease or radiation therapy, resulting in a prevalence of 1.5%. Of these three patients, only one was given bisphosphonates intravenously (i.v.), whereas all three had been treated orally. All three diagnoses of MRONJ had been previously known to the patients and their maxillofacial surgeons. Two of the patients had rheumatoid arthritis, and one patient suffered from large vessel vasculitis. Long anti-osteoporotic treatment duration, low functional status, and low bone density of the femur were significantly associated with MRONJ development. CONCLUSION: Inflammatory rheumatic diseases constitute a risk factor for MRONJ in patients treated with bisphosphonates for osteoporosis. Patients should be counseled accordingly and should be offered dental screening and regular dental check-ups.
BACKGROUND AND OBJECTIVES: The aim of the present study was to assess the prevalence of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients suffering from inflammatory rheumatic diseases, as well as to assess the prevalence of relevant dental, behavioral, and medical risk factors for MRONJ. MATERIALS AND METHODS: A total of 198 patients with inflammatory rheumatic diseases and osteoporosis therapy were recruited from a tertiary rheumatological/immunological referral center between June 2015 and September 2016. They were assessed using a structured interview. A maxillofacial surgeon later examined patients complaining of possible symptoms of osteonecrosis. In cases of osteonecrosis, dental records were obtained and evaluated. Preventive measures taken and dental as well as other clinical risk factors were evaluated. RESULTS: Of the 198 patients, three suffered from osteonecrosis of the jaw, none of whom had any history of malignant disease or radiation therapy, resulting in a prevalence of 1.5%. Of these three patients, only one was given bisphosphonates intravenously (i.v.), whereas all three had been treated orally. All three diagnoses of MRONJ had been previously known to the patients and their maxillofacial surgeons. Two of the patients had rheumatoid arthritis, and one patient suffered from large vessel vasculitis. Long anti-osteoporotic treatment duration, low functional status, and low bone density of the femur were significantly associated with MRONJ development. CONCLUSION: Inflammatory rheumatic diseases constitute a risk factor for MRONJ in patients treated with bisphosphonates for osteoporosis. Patients should be counseled accordingly and should be offered dental screening and regular dental check-ups.
Authors: Hiroko Okawa; Takeru Kondo; Akishige Hokugo; Philip Cherian; Jesus J Campagna; Nicholas A Lentini; Eric C Sung; Samantha Chiang; Yi-Ling Lin; Frank H Ebetino; Varghese John; Shuting Sun; Charles E McKenna; Ichiro Nishimura Journal: Elife Date: 2022-08-26 Impact factor: 8.713